Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo - PubMed (original) (raw)
Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo
Reuven Reich et al. J Enzyme Inhib Med Chem. 2015.
Free article
Abstract
Autotaxin is an extracellular, two zinc-centered enzyme that hydrolyzes lysophosphatidyl choline to lysophosphatidic acid, involved in various cancerous processes, e.g. migration, proliferation and tumor progression. We examined the autotaxin inhibitory properties of extended structure carbamoylphosphonates (CPOs) PhOC(6)H(4)SO(2)NH(CH(2))nNHCOPO(3)H(2), with increasing lengths of methylene chains, (CH(2))(n), n = 4-8. Carbamoylphosphonates having n = 6, 7, 8 inhibited autotaxin in vitro with IC(50) ≈ 1.5 µM. Using an imaging probe we demonstrated that compound n = 6 inhibits recombinant autotaxin activity in vitro and in vivo, following oral CPO administration. Additionally, daily oral administration of compound n = 7 inhibited over 90% of lung metastases in a murine melanoma metastasis model. Both the carbamoylphosphonates and the enzymes reside and interact in the extracellular space expecting minimal toxic side effects, and presenting a novel approach for inhibiting tumor proliferation and metastasis dissemination.
Keywords: Autotaxin; carbamoylphosphonate; carbonic anhydrase; matrix metalloproteinase.
Similar articles
- Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.
Fells JI, Lee SC, Fujiwara Y, Norman DD, Lim KG, Tsukahara R, Liu J, Patil R, Miller DD, Kirby RJ, Nelson S, Seibel W, Papoian R, Parrill AL, Baker DL, Bittman R, Tigyi G. Fells JI, et al. Mol Pharmacol. 2013 Sep;84(3):415-24. doi: 10.1124/mol.113.087080. Epub 2013 Jun 21. Mol Pharmacol. 2013. PMID: 23793291 Free PMC article. - Orally active, antimetastatic, nontoxic diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors.
Frant J, Veerendhar A, Chernilovsky T, Nedvetzki S, Vaksman O, Hoffman A, Breuer E, Reich R. Frant J, et al. ChemMedChem. 2011 Aug 1;6(8):1471-7. doi: 10.1002/cmdc.201100153. Epub 2011 Jun 8. ChemMedChem. 2011. PMID: 21656908 - Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Banerjee S, Norman DD, Lee SC, Parrill AL, Pham TC, Baker DL, Tigyi GJ, Miller DD. Banerjee S, et al. J Med Chem. 2017 Feb 23;60(4):1309-1324. doi: 10.1021/acs.jmedchem.6b01270. Epub 2017 Feb 10. J Med Chem. 2017. PMID: 28112925 Free PMC article. - Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions.
Benesch MG, Ko YM, McMullen TP, Brindley DN. Benesch MG, et al. FEBS Lett. 2014 Aug 19;588(16):2712-27. doi: 10.1016/j.febslet.2014.02.009. Epub 2014 Feb 19. FEBS Lett. 2014. PMID: 24560789 Review.
Cited by
- Dissecting the Process of Activation of Cancer-promoting Zinc-requiring Ectoenzymes by Zinc Metalation Mediated by ZNT Transporters.
Tsuji T, Kurokawa Y, Chiche J, Pouysségur J, Sato H, Fukuzawa H, Nagao M, Kambe T. Tsuji T, et al. J Biol Chem. 2017 Feb 10;292(6):2159-2173. doi: 10.1074/jbc.M116.763946. Epub 2016 Dec 27. J Biol Chem. 2017. PMID: 28028180 Free PMC article. - The Melding of Drug Screening Platforms for Melanoma.
Couto GK, Segatto NV, Oliveira TL, Seixas FK, Schachtschneider KM, Collares T. Couto GK, et al. Front Oncol. 2019 Jun 24;9:512. doi: 10.3389/fonc.2019.00512. eCollection 2019. Front Oncol. 2019. PMID: 31293965 Free PMC article. Review. - Understanding the Contribution of Zinc Transporters in the Function of the Early Secretory Pathway.
Kambe T, Matsunaga M, Takeda TA. Kambe T, et al. Int J Mol Sci. 2017 Oct 19;18(10):2179. doi: 10.3390/ijms18102179. Int J Mol Sci. 2017. PMID: 29048339 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical